New 'Double Punch' drug takes on advanced tumors
NCT ID NCT07016490
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new drug called SSGJ-709 in 15 people with advanced cancers that have spread. The drug is designed to block two immune system brakes (PD-1 and LAG-3) at once, potentially helping the body fight tumors. The main goals are to check safety and how the drug moves through the body, with a preliminary look at whether it shrinks tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SSGJ-709 (a bispecific antibody that targets two immune checkpoints, PD-1 and LAG-3)
What this could lead to
If this early trial shows safety and hints of tumor shrinkage, it could lead to a new treatment option for advanced cancers that have not responded to other therapies.
What could go wrong
This is a very early (Phase 1) and small (15 participants) study focused on safety, not effectiveness. The drug may cause side effects or fail to shrink tumors. Results may not apply to all cancer types.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Southern Oncology Clinical Research Unit (SOCRU)
RECRUITINGAdelaide, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••